… This grant builds upon the research from a prior grant: Validation of Sirtuin 3 as a … should reveal which groups of those with PD might benefit from SIRT3. …

… PD, indicating that cell death in PD may result in part from a loss of the protective action of ENSA against the … on the ability of ENSA to reduce neurotoxicity resulting from alpha-synuclein aggregate formation or the spreading of …

… This grant builds upon the research from a prior grant: Discovery of EEG Biomarkers for … our original results using a larger data set collected from several new sites. Once validated, we will develop …

… of nerve cells (neurons) in the brain resulting potentially from their inability to remove damaged mitochondria, which … protein degradation, can help remove damaged mitochondria from the neurons, but it must be activated in these neurons …

… biopsy and the skin cells called fibroblasts will be grown from the samples in vitro . This will allow us to assess … individuals with Parkinson's who are most likely to benefit from a mitochondria-targeting drug. These drugs are most …

… including those with PRKN and PINK1 mutations, will benefit from gene-specific, targeted treatment. This project aims to collect information on groups of people from different countries with these important but rare PD …